The invention and use of a large number of biologics during the last three decades for treating various deficiencies and chronic disorders has resulted in great benefit to human health. Abundant use of these biologics has been considerably constrained due to the reasons of their increased prices, charged by the inventors up to the time up to which their use were/are protected by intellectual property rights (IPR).Some of these biologics are presently being manufactured by the existing and newer companies as "similar biologics" after the IPR on these products have expired and as a result the prices of several such medicines are coming down."Similar biologics" are also referred to as "biosimilars" and other related names in different parts of the world. The regulatory authorities of different countries have authorized use of "similar biologics" based on comparative evaluation of each of such medicines with the inventor's biologics; these are approved when considered to be closely similar to the inventor's biologics in properties, quality and efficacy. By 2020, a dozen of "inventor's biologicals" having estimated market sale-value of over USD 79 billion are going out of protection of IPR. This would drive entrepreneurs to enter in to the field and the prices are going to crash considerably due to market competition. In course of time more "biosimilars" would go out of IPR. Different proactive governments and the regulatory agencies all over the world are trying to harness the existing and future opportunities by creating regulatory guidelines to ease faster authorization for use of "similar biologics" in their territories. Up to the present time, a small number of "similar biologics" have been approved for use in different countries all over the major parts of the world. More efficient technologies for manufacture of "similar biologics" are also getting developed. Together, these efforts are anticipated to ease the availability of "similar biologics" at more affordable prices to the users/ payers the world over.
INTRODUCTION
Modern biological drugs or biologics are manufactured by deploying recombinant DNA(r DNA) technology. Over the past three decades the development of biological drugs has experienced continuous growth. Chemically, such drugs are complex molecular substances which are produced by and within living cells of prokaryotic or eukaryotic origin. For the production of certain of such drugs, transgenic animals and plants are used. The cellular machinery of living entities synthesize such substances based on the 'commands' introduced by the scientists within the living bodies by utilizing r DNA technology. The molecular substances are 100 to 1000 times bigger in size as compared to the active pharmaceutical ingredients (APIs) that are used for the manufacture of generic pharmaceutical formulations. Almost all such biologically manipulated man-made molecular substances are initially protected under Intellectual Property Rights (IPR) by the inventors or their assignees.
IPR stipulates protection in countries where such rights have been taken. IPR becomes an expensive way to protect an invention if the invention is not exploited by the owner; many inventors therefore do not invest to protect their invention in every country. Earlier, protection was usually taken by the inventors in countries where inventors felt that the invention was saleable and the demands for the products emanating from the exploitation of the invention were anticipated to be high. Presently however the span of protection of inventions that are anticipated to be industrially exploitable fast is extended on a much wider canvas to cover as many countries as have demand for such products and where scientific capabilities of manufacturing such products exist in their territories, especially after the enactment of the provisions of World Trade Organization (WTO) in Member countries (1). ________________________________________ For the protection of inventions in Member countries, WTO has a uniform provision. Most countries in the world are presently members of WTO.
Protein-based biological drugs comprising mainly of simple or carbohydrate ligand-modified substances have a wide range of therapeutic applications. The business is very large in terms of global sale and therefore entrepreneurs have eyes on this business. The proprietary rights on such biological drugs are vested upon the inventors or their assignees as per the conditions of IPR.
As regards the contributions of the existing modern biologics in human welfare, these medicines have assisted significantly during the last two decades in treating chronic diseases including cancer. Use of various kinds of insulin manufactured through recombinant DNA technology along with other anti-diabetic drugs have resulted in the control of plasma glucose within healthy limits and death rates of diabetic patients between 1997 and 2006 have substantially fallen (2). Insulin has played a major role in such endeavour. Use of a large number of biological medicines to treat rheumatoid arthritis such as tocilizumab, certolizumab, etanercept, adalimumab, anakinra, abatacept, infliximab, rituximab, golimumab and tofacitinib has enabled clinical remission of the disease almost completely and has contributed to great human benefits; results with etanercept had been amazing(3). Treating cardio-vascular diseases by use of biological medicines such as thrombolytic agents like streptokinase, urokinase and tissue plasminogen activator, and monoclonal antibodies like abciximab (platelet aggregation inhibitor used usually during and after coronary artery procedures like angioplasty to prevent platelets aggregation) have saved many lives. Biological drugs have resulted in reduction in death rates from cardiovascular diseases by about 31% between 1998 and 2008 in the United States of America(USA or US) (4). Development and use of erythropoietin produced by modern biotechnology has reduced the need for blood transfusion in anaemic patients of different kinds including cancer patients and have reduced hospital days, thereby benefitting the society. This medicine has also prolonged lives of many terminally ill patients. Incurable viral diseases such as HBV and HCV have been controllable by use of a wide range of modern biologics such as interferons and pegylated interferons. A large number of monoclonal antibodies such as Nimotuzumab, Rituximab, Trastuzumab, Cetuximab etc . are continuing to provide substantial life expectancy gains. In US, the death due to all kinds of cancer has come down steadily by 1.5% per year from and during [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] , which is a reduction of around 17% over this period and is considered highly significant(5). Overall, the use of biological drugs has contributed to increasing life expectancy, decreasing disability and improvement in the quality of life (6).Several other independent studies have also shown that the biologic drugs have made most significant impact in prolonging and improving the quality of life of patients suffering from chronic disease conditions (7) (8) (9) (10) (11) . Therefore, wherever the burden of incidence of such diseases is showing increase, societal efforts require intensification to enable the availability and use of such medicines to the affected. Presently, because of increased costs of such medicines and the limited means of the payers in the poor countries, the situation becomes most vulnerable in families having to pay for the costs. The governments in poor countries also do not have adequate funds to make the necessary supply of such drugs to its citizens and in most countries the patients are the payers for the cost of their treatment.
Another dimension of human welfare has surfaced profoundly in all parts of the world which emanates from the increase in the number of elderly people (over 60 y) where providing a better quality of life to such population usually suffering from multiple chronic ailments is becoming a major problem worldwide; such persons infected with multiple chronic diseases would increase gradually over the years. Presently, little published information exists on how chronic conditions cluster and how judicious choice of medicines can be made to treat such conditions simultaneously. At the moment diabetes, cardio-pulmonary diseases, hypertension, arthritis, osteoporosis and a wide range of cancer are causes of co-occurrence of chronic diseases. Some empirical relationships of suffering from multiple chronic disease conditions in elderly patients could be associated with metabolic disorder syndrome such as obesity, glucose intolerance, hyperlipidimia and low serum content of high density lipoproteins (low HDL). In such multiple ailments, interrelationships are being worked out by understanding the detailed biology and the clinical manifestations of a group of such patients. This will result in planning for appropriate therapy and the biological medicines would play significant contributions in such endeavour. Such efforts of understanding the linkage among chronic diseases will be comprehended more profoundly in future and biological drugs along with others would contribute to treating such conditions (12).
In gist, it is anticipated that every country shall try to have abundant supply of cheaper but effective biological drugs in their territory to treat their population suffering from single or multiple chronic diseases.
With the passage of time, when such biological medicines get patent-expired, other new companies would come up and start producing them. Worldwide, the accepted practice for adoption of such patent-expired products for human use in medicines from manufacturers other than the original inventors are based upon proving and providing properties of the products manufactured by the new supplier/s as very similar to the products of the inventor through processes of comparison of the products physico-chemically, biologically and through accepted but limited clinical studies on human subjects. Such products introduced by new companies later-on are named differently in different countries(13-16) such as "biosimilars", "biosimilar products", "follow-on biologics", "similar biologics", "biologics against new biologics", "biocomparables" and "medicamento biologico similar". In India, these products are named as "similar biologics". In several international journals, such products have been termed as "Copycat" (17) and "Knockoff" (18) . In this review, the term "similar biologics" has been adopted for these products.
Each authorized "similar biologic" product is named by the manufacturers in their labels or prescribing information by an international nonproprietary name besides their trade name in order to ease precise recognition. The international nonproprietary name (INN) or the core name of the biologic substance is usually the name adopted for the drug substance internationally. The World Health Organization (WHO) had provided an update on INN for biologics (19) . As the "similar biologics" are highly similar to their biologic reference products, countries authorizing such substances are also allowing the use of the INN for the "similar biologics" on the label as well as in the prescribing literature. However, very precisely speaking, "similar biologics" are indeed not identical to the reference biologics. As the biologics are large macro-molecules and their structural complexities emanate from variations in the genetic processing entities as well as the manufacturing and downstream processing variations among manufacturers, there can be variations among the reference biologics and the "similar biologics" even though the difference cannot often be quantified at the beginning by utilizing the currently available scientific tools. But such non-noticeable differences might manifest adverse reactions on long-term use. "Similar biologics" are therefore, needed to be identified precisely for the monitoring of post-approval safety in order to identify and evaluate adverse reactions which may surface later on while using the products over a period of time, and which were not reported earlier (a phenomenon about which keeping a vigilance is called pharmacovigilance).For all new drug formulations, it is a practice to conduct pharmacovigilance studies to be vigilant about emergence of adverse effects on long-term use. Consequently, in some countries especially in developed counties strong bias exists to distinguish a "similar biologic" product from its reference product and other "similar biologics". Tackling this situation requires a standardized approach. One approach taken by some countries is through modification of the accepted INN.
Presently, among all nations, the United States Food and Drug Administration (USFDA) have taken a position in the context of INN naming of "similar biologics". In their guidance (20), the licensed similar biological products will include a core name and one designated suffix composed of four lowercase letters will be added to the core name of each product and will be attached with a hyphen. The core name of the biological product will be the name adopted by the United States Adopted Names (USAN) Council for the drug substance (21), which would generally be the INN for the reference biologics. Subsequently, the USFDA announced (22) that instead of one suffix, companies would be allowed to propose ten different suffixes, of which one shall be chosen and authorized by USFDA for the applicant to use in its literature.
Besides the present system of naming adopted by the USFDA, another way for addressing the issue may perhaps be through the use of US National Drug Codes (NDCs) with some modifications. In US, the NDCs are used for providing information about pharmaceutical products (23) although such codes are not compulsorily used in all the states throughout US. However, NDC's information is not presently used compulsorily for adverse events (AE) studies and perhaps there is inadequate familiarity among the medical practitioners about NDCs (24-25). However, it can be explore if the use of NDCs can be extended to identify "similar biologics" and if this can be made universal.
Some other countries such as Australia and Japan are tackling the issue in a different way, essentially by modifying the INN. Australia is in the process of coming out with its naming policy for "similar biologics". In Japan a suffix of "BS" is added to the INN to denote a biosimilar product. The naming policy of "similar biologics" is thus not yet universally consistent and congruent. One group has suggested that a US biosimilar naming policy along with a distinguishable prefix or suffix to the non-proprietary name of the reference product be used (26). In order to rationalize a uniform naming system for all "similar biologics" throughout the world, there is a need to evolve a uniform policy for all countries with a view to foster similar understanding for such products globally. It is useful to conjecture that any policy adopted for this purpose should not in any way promote quality-difference concept of such products with the reference biologics.
One alternative way is to prefix or suffix a code for each new-entrant "similar biologics" on the brand name instead on the INN; for companies introducing "similar biologics" only in INN , the prefix or suffix can be added on the INN for them.
In this paper, the business opportunities for the existing and the new entrants in the business of "similar biologics" in different countries, the technological choice options, the regulatory procedures to be complied with for marketing and the present status of approval of such products in major countries all over the major parts of the world and the new naming issues of "similar biologics" have been discussed.
METHODOLOGY OF STUDY
The current global status of "similar biologics" was assessed through an information search strategy which was designed based on information available on the websites of different governments, the WHO, the European Medicines Agency (EMA) and the USFDA. Google and other search engines were used to access information on biosimilars/"similar biologics" such as research and review articles published in international journals. Several keywords were used for conducting the search which includes biosimilars, biopharmaceutical companies, biomedicines, clinical trials in biologics, data-marketing exclusivity, technological processes for biosimilars, patent expiry of monoclonal antibodies and biologics, nomenclature plan of biosimilars etc. The websites of important manufacturers of biologics were also searched. Technological information including productspecific yields was collected through the search engines. Discussions were also conducted with certain knowledgeable Indian manufactures of "similar biologics". The author had hands-on experience in developing and manufacturing aspects of a couple of "similar biologics" in India.
GLOBAL AND NATIONAL MARKET SCENARIO FOR SIMILAR BIOLOGICS
The global market for "similar biologics" was anticipated to grow to USD 10 billion in 2015(27) . The future growth is largely driven by some twelve numbers of "inventor's biologicals" going off patent(28)in USA and Europe by 2020 worth market sale-value of over USD 79 billion which include Adalimumab (Humira),Insulin Glargine(Lantus),Etanercept(Enbrel),Infliximab( Remicade),Rituximab(Mabthera),InsulinAspart(N ovomix,Novorapid),Bevacizumab(Avastin), InterferonBeta1A(Avonex,Rebif),Trastuzumab(H erceptin),GlatiramerAcetate(Copaxone),Pegfilgras tim(Neuiasta) and Ranibizumab (Lucentis). The loss of exclusivity in intellectual property rights would drive the existing as well as the new entrepreneurs to enter in to the field and the prices are going to crash considerably through market competition, once these products are introduced as "similar biologics". In course of time more numbers of "inventor's biologics" would go out of patents protection and therefore the opportunities for the manufacturers of such drugs are anticipated to enlarge.
The number of companies likely to enter into "similar biologics" market would be large even though the numbers in absolute terms would not be enormously large, as the lead time in the development of such products is high ,would require high investment costs and the technological complications are intricate. Such "similar biologics" are "different" from "patent-expired small molecules", where (in the latter cases) the developmental requirements are much simpler. "Patent-expired" small molecules are parts of outfits of "generic drugs" manufacturing.
"SIMILAR
BIOLOGICS": COMPLEX PRODUCTS BUT ATTRACTIVE FOR ALL COUNTRIES "Similar biologics" are biological entities that have been introduces after the inventor's biologics. During the recent times, there has been newer and novel understanding of the molecular and cellular basis of complex diseases such as arthritis, psoriasis, multiple sclerosis, complications of prolonged diabetes, cardiovascular diseases, neurological disorders and a wide range of cancer. In order to contain such disease conditions and to impart better quality of life to the diseased individuals, biological drugs have been invented which have shown much better efficacy over the small molecular entities and therefore more emphasis is being made to develop more effective new biological entities. Such biological products are essentially proteins in nature and include a wide range of substances starting from relatively simpler molecules such as protein-based disulphide bond-rich antigens, hormones, glycosilated proteins, pegylated proteins, cytokines, monoclonal antibodies, bispecific antibodies, antibody fragments, antibody-drug conjugates, radio-labelled antibody conjugates, Fcfusion proteins, albumin-binding domain antibodies, carbohydrate antigens, plasmids, nucleic acid-based products and vaccines, cellular products for therapy and gene therapy products , and devices related to cell and gene therapy. In this review, only the protein-based products have been considered which include protein-based disulphide bond-rich antigens, hormones, glycosilated proteins, pegylated proteins, cytokines, monoclonal antibodies, antibody fragments, antibody-drug conjugates of all kinds and albuminbinding domain antibodies. Proteins are polymers of alpha amino (most frequently L-α-amino) acids with defined sequences linked by peptide bonds and having usually more than forty alpha amino acids in each molecule but can go even up to 2000 amino acids or more. In these products-baskets, presently there are about 50 therapeutic monoclonal antibodies of inventor's products approved globally and that the turnover of these products in 2013 worldwide was about US$ 75 billion. It is anticipated that by2020, nearly 70 monoclonal antibody products shall be approved globally (29), the turn-over value of which has been estimated at US $ 125 billion at current prices.
As many of the inventor's biologics are going out of patent or have already reached such status, other companies are feeling the urge of getting into the business as fast as possible so as to reap benefits from their sales. However, entering into this business which is highly science based and technology oriented is not easy. All these products in the form of molecules are produced within living cells; such cells can be prokaryotic or eukaryotic in nature and have been modified by use of recombinant DNA technology. Such cells are grown and conditions are so set as to direct such living entities to synthesize these molecules. These molecules are large and often very large in molecular size, presented as alpha amino acid polymers connected by peptide bonds and making them complex in final tertiary or quaternary structures. The primary structures are made up of chemical covalent bonds between and among the alpha amino acids; he primary products are processed by the cellular machinery into secondary, tertiary and sometimes quaternary structures creating contours on their surface as well as within the core, "pockets" of diverse electronrich or electron-deficient as well as hydrophobic or hydrophilic regions. Weaker structural bonds are created by hydrogen bonds, ionic bonds, and van der Waals attractions. Such individual noncovalent bonds are 30-300 times weaker than the covalent bonds but when in contours many numbers of weaker bonds act in parallel, these contribute to holding two or more regions of the polypeptide chain tightly together. The eventually evolved three dimensional structures evince biological activity. Such structural contours are essential and critical for their biological activities as most biological interactions are based on ligandreceptor interactions that trigger the manifestation and/or modulations of diverse biochemical reactions in the cellular environment where these products are active. The active bio-molecules are either a part of the cellular entities or are secreted into the surrounding medium by the living cells that synthesize them. In either case, the isolation process of the active ingredients is complex requiring separating them out in sufficiently pure form, often more than 98% in purity assessed on sophisticated analytical instruments. It requires great skill to separate out the desired product in such purity when their initial concentration is substantially low (micro gram to milligram gram quantities per litre of cell-soup) and are surrounded by cell debris, other proteins, liquids, salts and different kinds of metabolites generated during the cell growth operations. Because of complex biological environment, part of the target products is likely to be modified through cellular processes of modifications. Besides, the products are associated with contaminants and endotoxins. In order to ensure the presence of exactly the same variance from batch to batch is also another difficult task to establish. The targeted product has to be isolated and purified to the same degree of purity from batch to batch, which is again a task requiring maintenance of stringent conditions in order to eliminate variation in operating conditions from batch to batch. This also requires use of same qualities of input materials which again can lead to variations in results especially if these are agriculture based materials and cannot therefore often be fully defined. In addition, process related variables are also to be minimized to eliminate product quality difference from batch to batch.
High technical skill, strong discipline and maintenance of uniform conditions throughout the processing cycles are the cornerstones for success in order to minimize batch to batch variations in the product qualities. In certain types of biologics, the primary products obtained from the cell soup after purification requires further processing invitro in the laboratories under stringent conditions. The biologics are to be authenticated through stringent in-process controls. The final product requires quantitative characterisation by physicochemical and biological testing methods utilizing sophisticated instruments. The processes are usually not generic and vary considerably from product to product even though certain conditions of creating and maintaining the infrastructure facilities are common, emphasizing unidirectional flow of man and materials, maintenance of cleanliness of high standard in the production areas and isolation of the finishing area from other areas so as to minimize the chances of crosscontamination. Once the biologics are ready for conversion into formulations, these are formulated and packed into the finished products. These are released after rigorous quality control endeavour.
Unlike the small molecules where the active pharmaceutical ingredients and the finished formulations manufactured wherefrom are subjected to quality, purity and stability studies, the biologics are subjected to additional checking for potency, immunogenicity, stability and compatibility. For new biologicals, the first-time authorization for sale is imparted by the regulatory authorities only after satisfactory pre-clinical and clinical studies besides the above. For new biologicals, there is often no initial biologic product for use as a standard and therefore their evaluation is more exhaustive and stringent especially on pharmacovigilance information. On the other hand, for "similar biologics" (or biosimilars), pre-clinical studies as well as abbreviated clinical studies are required using the "reference biologic product" as the standard, and therefore becomes simpler. The main difference in the unit cost of new biologicals and "similar biologics" arise from the large difference in the cost of pre-clinical studies and the clinical studies experiments for the former than the costs incurred thereon for the latter.
It can be stated in general that even though the technological inputs and the process requirements for biologics are complex, these can be duplicated with proper inputs of skills, investment and planning. The entrants of "similar biologics" manufacturers are allowed to seek approval at least ten to twelve years (30-32) after the inventor's products are in the market, depending upon whether they are seeking permission in European Union (EU) or in USA. In other words, the actors of "similar biologics" have enough time to plan.
By proper choice of the product to be manufactured, the investors of "similar biologics" hold the potential of reaching high business volume within a short period of introduction of their products in the market as the market volume is very large and a part of it can be captured; the major driving force for entering in to this sector is that the profitability in the sector is high for the first entrants and therefore ensuring fastness in every aspects of the planning and implementation is important.
Setting up of "similar biologics" industry would ensure the availability of such drugs from multiple sources resulting in market competition and therefore, the prices would also be cheaper and more affordable than when supplied by the "inventors". The impression all over the world is that the "inventors" have been charging exorbitantly high prices for such drugs till the patent rights are enforceable (33) and as a result such drugs are often unaffordable by a common man. In many countries while the biotherapeutic products purchased by the Government represented (in dosage units) a small percentage of prescribed medicines for their people, in terms of money spent these accounted for substantial portion of the total expenses. In Brazil, biotherapeutic products represented 2% of the medicines prescribed but accounted for 41% of the annual budget of the Ministry of Health of that country (34). In EU region, the first "similar biologics" was approved in April 2006 (Omnitrope of Sandoz, which is somatropin); the EU thereby acquired more practical experience in the use of "similar biologics" along with the "reference products". It was found in EU region that up to the present time, the prices of "similar biologics" were 20-30% cheaper (35) than their "reference products", thereby contributing to substantial saving in treatment costs.
The "similar biologics" approved by the European Medicines Agency (EMA) up to the present time were seven separate classes(36)of "similar biologics" namely human growth hormone (somatropin),erythropoiesis stimulating agents (erythropoietin in its natural and its long acting versions),granulocyte colony stimulating factor (G-CSF also known as filgrastim) as well as its pegylated form, follitropin alpha, infliximab, insulin glargine and etanercept.EU introduced the EMA pathway, which is in vogue for more than a decade. In EU "similar biologics" have impacted several European countries in terms of competitive performance in healthcare systems, cost savings and gain in substantial market share of and from the sale of "reference products". A study based on the audit data from Intercontinental Marketing Services (IMS) on two of the above classes of drugs namely erythropoiesis stimulating agents in various forms (erythropoietin in its natural and its long acting versions) and the granulocyte colony stimulating factor (G-CSF) as well as its pegylated long-acting form during 2009-2011 in five EU countries namely Germany, United Kingdom, Sweden, France and Italy was conducted. The results showed that due to cheaper unit prices of "similar biologics" resulting in cost saving, these products acquired significant shares of the market relative to the market shares of the corresponding "reference products" for both the first generation products as well as for the long-lasting second generation products; the latter products were able to acquire more share of the market. The indications from the analysis were that manufacturers of "similar biologics" would be capturing sizeable part of the market of "reference products", but at the same time would be in constant pressure for developing the next generation "similar biologics" including "biobetters" through incremental innovation implying that such companies would have to resort to constant R&D to move into introducing products of better characteristics to remain competitive. "Biobetters" are biosimilar products that seek superiority in one or several aspects of their clinical profile over the "biosimilar" products and therefore from regulatory point of view would require complying with additional regulatory pathways for approval and use. When "similar biologics" or "biobetters" are introduced, it implies that there would be cost savings to the society and that the competition shall be more severe when more complex biological products get introduced through such options requiring to invest more in technology as well as in R&D, thereby considerably eroding the cost advantage. The future directions in the development of "similar biologics" for more complex molecules and technologies would be more complex and are yet not fully clear (37).
The cost of treatment using biologics like "reference products" in the US has been estimated to be US$ 45 per day or US$ 16425 per year compared to the treatment cost of patients with traditional pharmaceuticals at US$ 2 per day or US$ 730 per year depicting more than 20 times the treatment cost using biologicals (38) .
From this information, it is clear that even in US, the treatment cost using branded biologic products is very high and would be unaffordable by many kinds of patients living in different economic situations and conditions. The high cost of "inventor's biologics" has become an important issue therefore in USA as well as all over the world in the battle of containing the ever-increasing healthcare costs.
In the USA, the country enacted in March 2010 its Biologics Price Committee and Innovation Act of 2009 (BPCIA) as an endeavour to provide affordable care to its people through its Patient Protection and Affordable Care Act (popularly known as Obamacare) in order to authorize approval of biosimilar products by USFDA. The approval pathway was defined under section 351(k) of the US Public Health Service Act where applicants for "similar biologics" are to demonstrate that the products are safe, pure and potent for the approved conditions of use as of the originator products. Following the enactment of the approval pathway, the cost saving potential from the use of "similar biologics" in USA is being worked upon by various agencies, even though during the time of writing this article only four "similar biologics" namely Zarxio (G-CSF/Filgrastim) of Sandoz; Inflectra (Infliximab) manufactured by Celltrion Inc (and to be marketed by Pfizer); Erelzi (Etanercept) of Sandoz (a Novartis company); and Amjevita (Adalimumab) of Amgen Inc were approved by USFDA for use in the country(39). It has been predicted that use of "similar biologics" will lead to a reduction (40) in US$ 44.2 billion (range US$ 13-66 billion under various assumptions) in direct spending on biologic drugs in USA from 2014 to 2024, which amount is considered substantial. US therefore shall have profound interest in the introduction of "similar biologics" in their country.
The new treatment options especially of certain chronic diseases utilizing biologic medicines have brought considerable hope of increasing the quality of lives of patients even though the treatment cost remains high. During the last three decades about 80 biologic molecules produced by recombinant DNA technology have been launched globally to bring in new treatment options for life threatening chronic diseases. These include about 30 therapeutic proteins and another 50 monoclonal antibody-based products. "Similar biologics" medicines are subsets of the biologic medicines. Presently though the share of biologic medicines by value of the global market of pharmaceuticals is low, projections have been made that this sector will account for up to 28% by value of all pharmaceuticals used globally. It is also projected that global biologic medicine share by 2020 would exceed US$ 390 billion. It has also been calculated that the cumulative potential saving to the healthcare cost in selected European markets and the US market as a result of using "similar biologics" may be above Euro 50 billion in aggregate over the next 5 years up to 2020 and may even be as much as Euro 100 billion (41) if there are changes in treatment options with greater choice for "similar biologics" made by the payers, physicians and the patients. These figures are indicators of the potentials of "similar biologics" in the near future. In the present day situation of constrained budgetary environment of most actors, it is anticipated that the global community will move towards utilizing the maximum potential emanating from the use of "similar biologics".
It is relevant to mention that while the phenomenal technological progress in fulfilling the unmet needs of humankind shall bring in more comforts in different facets of human life, some of these would also be reasons for developing and spreading illness in humans. Some illness will emanate from the enforced increased sedentary habits in human, many others shall evolve from the transformation of infective living entities especially some microbes and some others would evolve from induction of systemic defects from continuous exposure to electromagnetic radiations. There would therefore be greater urgency to develop newer medicines to treat illness where there are anticipated to be substantial unmet needs. The developments shall certainly be increasingly challenging and the researcher shall have to understand more of the biological basis of causation and progression of illness. The researchers in biopharmaceutical sector shall therefore be engaged in coming up with newer biological substances to intervene on the cause of such illness and these efforts shall foster innovation. The development of innovation biologicals would be expensive and therefore the newer products shall continue to be expensive. The manufacturers of "similar biologics" would have to wait to introduce such products from their manufacturing facilities till the IPR expires. In the meantime however, the "similar biologics" companies would have to materially upgrade their R&D efforts to understand profoundly how such novel products work and how such products can be made to maintain physico-chemically a stable status and biologically in active form for long periods after manufacture. If "similar biologics" companies upgrade their research capabilities to profoundly advanced stages, then only such companies shall be able to reap more benefits from newer biological products after the expiry of IPR on them.
PRESENT DOMINANT MARKETS &TECHNOLOGICAL ASPECTS OF "SIMILAR BIOLOGICS"
The most dominant markets of novel biopharmaceuticals including "similar biologics" as also the technologies required to steward these products forward in order of dominance are concentrated in North America (USA & Canada), Western European countries (especially Germany, UK, France, Spain and Italy), China, Japan, India and South Korea. Some South East Asian countries, the whole of South America, Australia, Russia & CIS countries are dormant at the moment but hold potential for faster growth in "similar biologics". The need for "similar biologics" in African countries is rising very fast because of faster increase in the incidence of chronic diseases and cancer in certain regions. Because of the impact of several other factors such as rise in the population of middle class, demanding more of upto-date treatment of chronic disease, increase in the infrastructure of medical services providers, more skills gained by the medical profession to treat complicated disease conditions, the introduction of some "similar biologics" resulting in reduction of prices of treatment costs, the growth of markets have been more in regions like China and India followed by North America, Western Europe, South America and South East Asian countries(42). While planning for the setting up of infrastructure for the manufacture of "similar biologics", these aspects of markets are to be kept in view.
In "similar biologics" manufacture, the titers obtained for the products as measured in terms of grams of target proteins(active biological ingredients) per unit volume of the bioreactor, the time taken for reaching the optimum titers measured in time from the start of cell culture process in the bioreactors, the recovery of "similar biologics" measured as the percentage of purified product obtained from the total mass of the active substance in the bioreactor at the point of harvesting a batch are the key measures that determine the operational efficiencies and cost of production. While the "similar biologics" products are to have quality traits not less than the quality traits of the reference products, the manufacturers are on pressure from the governments, the patients and the society to supply such products at most optimum rational costs. There is therefore an unstinted pressure on the manufacturers to have maximum manufacturing efficiencies so as to enable the sale of their products at most competitive prices. In order to understand the stages where technological inputs profoundly determine the manufacturing cost, the general manufacturing steps need to be assessed. The above flow sheet ( Figure 1 ) depicts schematically, the major steps involved in the manufacture of "similar biologics".
Escherichia coli (E.coli) cells are used for the manufacture of a few "similar biologics" which are not glycosilated; these include production of insulin, somatropin, antibody fragments such as Fabs etc. Cell lines of Saccharomyces cerevisiae and Pichia pastoris have also emerged (43) as promising microbes for producing certain cytokines and monoclonal antibodies. Most other products are manufactured using mammalian cells. Only a few cell lines such as Chinese Hamster Ovary (CHO), NS0 murine myeloma cells, PER.C6 human cells and certain others have been used for producing monoclonal antibodies (44).In order to ensure high productivity with profound attributes towards quality, the selection of right quality of cell lines is very important and critical. Among the mammalian cells, the CHO cell lines have rapid growth characteristics, high expression of target protein and can be adapted for growth in chemically defined media, thereby minimizing the chances of batch to batch variations in product qualities. Because of these attributes, CHO cell lines are preferred mammalian cells for biologics and "similar biologics" manufacture. While developing or for making a purchase decision of technologies, the selection of well established and well characterized cell line based technologies make a judicious and intelligent choice.
Out of some 174 recombinant proteins and antibodies currently approved in US or EU, 76 numbers of products are manufactured in microbial production system mainly in E.coli and yeast; 91 products are manufactured in mammalian cell lines of which 60 are made in CHO; 4 products are made in insect cells; 2 in transgenic animals, one each in goat and rabbit; and 1 product made in carrot cell culture (45).
Most of the older production facilities are based on establishment of stainless steel (SS-316) bioreactors equipped with pre-and post harvesting facilities. Such bioreactors are usually established in the range of capacities of 1 kilolitre to 50 kilolitres but closer range is between 2 to 25 kilolitres. The production is usually carried out on fed-batch culture mode as also continuous perfusion mode (46-48).
The outputs from the production of bioreactors in fed-batch mode usually limit the overall production capacity. Presently, gross productivity in terms of titers in the bioreactor are in the range of 1-5 gm/L in 10-14 days fermentation time with some companies achieving 10-13 gm/L on extended duration of culturing. Usually a titer of more than 3 gm/L is considered as average titer for the industry engaged in the production of biologics. Various percentages of recovery of the biologics have been reported in the literature with high figures around or above 80% and the low figures of 65-70%. However, the industry average for products manufactured through mammalian expression system including monoclonal antibodies is usually low and can be considered at 70% rather than 80%. The product recovery time is typically not more than 2 days. The titer, the yield and the processing time vary from product to product but usually are within the range indicated above. Using these data(45,49), on a continuous working basis with reasonable downtime for routine and annual scheduled maintenance, the productivities at 70% recovery on attainment of a titer of 3 gm/L in the production fermenter in 12 days, the per litre productivity of installed fermenter volume at 80% loading would work out to 3 gms/L X 0.8(fermentor loading) X 2.5(batches per month) X 12(months in a year) X 0.7 (recovery efficiency)X0.95 (fermentation sterility) gms/L or 47.88 Kg/kilolitre (KL). On attainment of average titer of 5 gms per litre, this figure would be 79.80 Kg/KL. Using a set of 4 numbers of 2KL production fermenters with matching pre and post fermentation operations, the annual production capacity is anticipated to be 383.04 Kgs/Y, say 380 Kgs/Y at 3 gm/L titer and 638.4 Kgs/Y say 640 Kgs/Y at 5 gm/L titer respectively.
These figures can be used as benchmarks while installing local plants or negotiating for technology purchase. These would avoid going into the intricate aspects of technology assessment in the first round.
Several operators have resorted to perfusionculture mode of production where fresh media is continuously fed into bioreactors while growth inhibitory products are continuously removed. In such operations, cell densities of the mammalian cells increase considerably and may reach (50) levels of 3 X 10 7 to 1X10 8 cells per ml whereas in fed-batch system the levels are about 5 X 10 6 to 2.5 X 10 7 cells per ml. The size of the bioreactor is also substantially reduced in case of perfusion-culture mode of production. There are certain kinds of advantages however in fed-batch mode, which issues are not discussed here. Of late, another system of production is becoming popular where production appliances are made up of plastics and such systems are for one-time use. Such single-use systems(SUSs) are fast developing and replacing the conventional stainless-steel bioreactors as well as the piping and other pre and post fermentation processes; indeed in certain developed countries ,these technologies are becoming more popular. A large number of biopharmaceuticals are produced in SUSs in perfusion culture by a number of companies such as Bayer, Eli Lily, Genzyme, Janssen, Merck-Serono and Novartis (51).
The SUSs bioreactors and the upstream as well as the downstream SUSs are " disposables" manufactured from a varied range of plastic materials such as cellulose acetate (CA), polyvinyl chloride (PVC),ethylene vinyl acetate (EVA), polycarbonates(PC) synthesized from bisphenol-A and phosgene, polyethylene (PE) manufactured by polymerization of ethylene oxide, nylon type polyamides (PA), polyethersulfone (PESU) produced by the condensation of suitable bisphenols and bis(4-chlorophenyl)sulfones, polypropylene(PP) produced by polymerizing propylene oxide, polytetrafluorethylene (PTFE)etc. The SUSs products include a wide range from bioreactors, mixing vessels and filling systems, a wide range of filtration systems, pumps, centrifuges, chromatography systems, freeze & thawing systems, isolators, tubing, connections, plugs, seals, transfer systems, sampling systems and a whole lot of work equipment.
The SUSs are becoming so versatile that these are being available for carrying out multiple types of unit operations in the upstream processing areas such as storage and transfer of solids and liquids, dissolution operations, filtration of mixtures, homogenisation of fluids where required, dispersal of droplets and gas bubbles and operations for transfer of materials to obtain phase interfaces. Equipment for use in the downstream operations such as dead-end sterile filtration, cross-flow filtration including ultrafiltration and diafiltration, functional filtration including membrane absorption such as affinity and ion exchanger processes as well as various kinds of chromatography in the small scale such as cation exchange, anion exchange, hydrophobic interaction chromatography and mixed-mode chromatography can be carried out. There is however, gap in the use of large scale chromatographic operations as well as in the availability of adequate spectra of sensor equipment. Other than these two areas, most SUSs can be comparable to SS-system. In other words, all the unit operations and unit processes that are required to be carried out using SS-system can also be carried out using SUSs. Thus, the equipment, system designs and components are holding the potential of taking over the processes and operations used in SS-system as more scientific developments take place in these areas (52).
In a new setup, SUSs have to contribute to equivalent, if not better, overall attributes compared to the overall performances achieved in fed-batch SS-systems. In the manufacture of biologicals, SUSs have to contribute to high patient safety of formulations on one hand and on the other side these would have to ensure prompt supply (systems and equipment) to the manufacturers. In eventual acceptance of SUSs, these should yield overall lower cost of production to be acceptable by entrepreneurs. The regulatory requirements for maintaining the quality of the products especially on the concerns from extractables and leachables have been evolving and the regulatory documents from US FDA, EMA, ISO, ICH, WHO etc. which provide guidance for maintenance of standards need to be complied with by the manufacturers and suppliers of SUSs. Fortunately, the present suppliers of SUSs are themselves conducting considerable in-house test to ensure compliance with regard to international and statutory guidelines. Many such companies are also certifying for compliance for robust regulatory package based on which biologic companies procuring them can proceed, thereby reducing the need to conduct tests for cleaning and validation which also results in lesser documentation needs. The use of SUSs result in saving in labour and materials for portions and parts of the process requirement for maintaining sterility of the bioreactors as well as the pre and post handling systems as the systems are supplied and guaranteed sterile. SUSs are sterilized by gamma radiation and therefore ensure total sterility. As a result of use of sterile equipment, there is considerable saving in the use of large volumes of high quality water (injection grade), chemicals and labour. These costs are unavoidable for SS bioreactor system. SUSs, also require lesser space for storage area. There are issues of requirement of larger quantities of waste management when SUSs are used. Disposal of such wastes in land filling or in recycling of plastics in other safe areas are controversial and also result in incurring costs by the users. Newer methods such as by burning and concomitantly generating steam and electricity can be explored to make the SUSs more economical (53).
Presently, the main limitations on the use of SUSs are high procurement cost, supply security and uncertainties in assuring absence of leachable and extractable from the plastics. All the SUSs require sterilization by gamma ray irradiation processes. Such facilities are not in place in many parts of the world. Besides, other limitations include small range of operable pressure range, limited flow rates, inadequacies in generating adequate centrifugal forces, working temperature range limitations, gas ( oxygen and carbon dioxide) stripping rates from systems where required. Further, employee training, quality assurance and standardization of production processes are other issues. Interestingly, these limitations are fast being addressed by the suppliers especially in the developed country regions.
The decision to go for SUSs for the manufacture of biologics and "similar biologics" instead of the long used and well established SS systems would depend upon the place and the country where such systems are being installed, the products to be manufactured and the processes to be chosen. This shall also depend on the long term business objectives of the organization. To obtain fully compliant plastics from proven suppliers having established reputations without having to fetch frequent change notices from the vendors are issues a manufacturer has to consider. There are several other issues like continuous and timely availability of materials, components and system design requirements of SUSs, on which unreliability of supply can seriously jeopardize production schedule. In many countries on overall consideration, the use of SS-system would continue to prevail for another one decade over the use of SUSs especially in regions where significant growth in demand for "similar biologics" is getting generated in local emerging markets such as India, China, South East Asian countries and Southern American countries, where the local governments are also promoting the establishment of "localproduction" infrastructure.
NEW REGULATORY FRAMEWORKS EMERGING WORLDWIDE FOR "SIMILAR BIOLOGICS"
Worldwide, because of emerging large and growing market of "similar biologics" emanating from the benefits derivable from their use for containing certain chronic diseases and conditions, almost every country is taking steps to ensure the availability of such products within their territory either by local manufacture or by imports by easing the procedures for imports. The regulatory frameworks of all major countries are fast emerging to provide speedy structured approvals so as to enable the consumers to get the benefits of use of such medicines within their regions. There is however considerable resistance from certain countries particularly from the US regulators to formally approve the production of "similar biologics" from new "similar biologics" manufacturers for use in their territory. The main reasons appear to be to ensure that the products approved provide to the patients the highest standards of quality, safely and efficacy comparable to the inventor's reference product. Perhaps there are doubts that approval of "similar biologics" in different countries does not go through the same stringent processes of data generation and data scrutiny, a situation which has not been rationalized and standardized globally.
SIMILAR BIOLOGICS APPROVAL PROCEDURES:
COUNTRY-SPECIFIC DEVELOPMENTS The competitive pressure as well as the market for "similar biologics" varies from country to country. World over, there are "regulated markets" as well as "semi-regulated markets" for "similar biologics". The highly developed countries such as USA, Canada among the western countries, the whole of European countries including Norway, Netherlands, UK, Germany, France, Sweden, Switzerland, Belgium, Italy etc and Japan among the Asian countries have strong policies for introduction of "similar biologics" in their territories. The Australian guidelines for "similar biologics" are also similar to those as found in the highly developed regions and were based on the EU guidelines.
Among the Asian countries, India, China and South Korea have a large number of "similar biologics" introduced in their territories. The ASEAN countries are active through their Association for the development of a common technical dossier though the guidelines have not yet been finalized and adopted for biologicals and "similar biologics" in all the ASEAN Member States. Some ASEAN countries have in the meantime come out with their "similar biologics" policies.
Among the South American countries, Brazil, Bolivia, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru and Venezuela are countries that have approved one or more "similar biologics" or "biosimilars" for use in their territories.
Among the nine Common Wealth of Independent States (CIS), the main market in terms of consumption is anticipated to be Russia (2015 population was 146.27 million) followed by Uzbekistan (2015 population was 31.025 million), Kazakhstan (2015 population was 17.417 million), Belarus (9.475 million in 2015) and Azerbaijan (9.356 million in 2015) ; the combined population of the five countries was more than 91% of the total population of the region. In terms of per capita GDP (2012), Russia was on the top followed by Kazakhstan, Belarus, Azerbaijan and Uzbekistan (54). In all these CIS countries, the procedures for introduction of "similar biologics" are gradually evolving.
In all countries, the regulations for approval of "similar biologics" are based on proving the comparability of the products to an already approved reference product. The comparability measurements are defined in terms of quality, nonclinical physico-chemical identification and evaluation of products and processes and finally a clinical evaluation. The "similar biologics" are biotechnologically manufactured gene expression products which are essentially recombinant protein products. In all the countries, the abbreviated pathway package requires full quality assessment of the products by physico-chemical methods using most sophisticated instruments. There is however a relaxation in the generation of comparative clinical studies which situation varies from country to country. A minimum comparative clinical study is required with comparators of each clinical indication. In terms of quality studies, extensive physico-chemical experimentations are required to demonstrate physico-chemical properties, biological activities, immunological properties, impurities profile, purity characteristics and stability data. All the analytical techniques are to be the state-of-the-art techniques and technologies that are capable of detecting small differences in quality attributes. The impact of the observed differences of the "similar biologics" with the reference drug is to be assessed based on which the clinical studies are designed. Each country decides the acceptability criteria in the dossier to be prepared and submitted. All nonclinical study data are designed to be comparative in nature. The reference product in every country is considered to be a drug that has already been approved by a regulatory authority on the basis of submission of full regulatory dossier. Always the reference products are used for demonstrating the comparability of "similar biologics" with reference to quality, non-clinical and clinical studies. The "similar biologics" are converted into dosage forms, strength and root of administration, which essentially have to be the same as that of the reference products. In many cases where the reference product is not available in the local market, the reference products can then be procured from another country based on full information of approval of reference product. For conducting the clinical studies, pharmacokinetic as well as pharmacodynamic data generation are mandatory. Clinical studies are conducted in a comparable manner using the reference product. Even though a similar biologic product shows adequate comparability to the reference product for one indication, it is usually not allowed to extend the approval of similar biologics to all other indications of the reference product without generating clinical data. In some counties however exceptions are made on the basis of the argument that the mechanism of action for the "similar biologics" shall be the same as that of the reference product. Usually in such situations for extrapolation of indication, a case by case analysis and approval has been considered to be more rational. The WHO Guidelines (55) on evaluation of "similar biologics" is comprehensive and is based on a comparative study of the "similar biologic" product with the previously licensed reference product comparing the quality, safety and efficacy. While developing Guidelines for approving "similar biologics", many countries have used the WHO Guidelines as the basis in formulating their authorization document.
The major country-wise regulatory framework as well as the approved "similar biologics" are provided below.
USA
The US Government enacted its Patient Protection and Affordable Care Act (Affordable Care Act) on March 23, 2010 amending its Public Health Service Act (PHS Act), thereby creating an abbreviated license pathway for biologics that can be demonstrated to be "biosimilar" to or "interchangeable" with FDA's licensed biological product. The developers of "biosimilar products" seeking license for manufacturing such products , also identified as the biologics license application (BLA) holders, required clarification on certain questions like the type and extent of data requirements for proving what "biosimilarity" and " interchangibility" would mean in reference to the inventor's US FDA approved biologics; how applications are to be submitted to US FDA for obtaining approval; and issues relating to whether there existed unexpired orphan exclusivity for any indication for which the reference product is licensed. The US FDA subsequently therefore, in April 2015 published its "Guidance for Industry" for introducing "biosimilars" in the country (56)for easing and bringing in more clarity. Presently, four "biosimilar" products in four brand names have been approved by the country as per information below in Table 1 .
CANADA
Health Canada is the federal regulatory authority to provide authorization for the manufacture of "similar biologics" in the country. Such products are termed as "subsequent entry biologicals" (SEBs) in Canada. Authorization of sale of SEBs is based on demonstrated similarity to a previously approved biologic drug in the country. The Biologics and Generic Therapies Directorate (BGTD) of Canada is the regulator of biologic drug for human use, which provides regulatory oversight of such products with comprehensive reviews covering quality, safety and efficacy, lot release and on-site evaluation. A sponsor has to name the reference biologic drug authorized in Canada to which the SEB will be subsequent. Sponsors of SEBs consult the BGTD for regulatory guidance at any stage of development. Information for submission requirement for SEBs is on the internet (63). Presently, four "similar biologics" in five brand names are approved in Canada as provided in Table 2 (64).
EUROPEAN UNION
In EU, the market authorization for "similar biologics" is provided by the European medicinal Agency (EMA). These products are generally categorized as "similar biological medicinal products'' by the EU. The EU had been active in creating the legal framework for approving "similar biologics" from 2003 and came out with a draft in April 2005 which draft became effective from 01/06/2006(70). This framework was for approval of "similar biologics" by an abbreviated registration process. Later, the guidelines had undergone changes and as of date the latest guidelines came into effect from 01/06/2015(71). These guidelines recommend a step wise conduct of non-clinical and clinical studies to generate data to show that the product for which approval is sought is similar to the reference biological product. Up to present time, 23 "similar biologics" had been approved by the EU, of which two were withdrawn by the applicants; these include one brand of filgrastim, withdrawn in April 2011 and the other for Somatropin withdrawn in May 2012. The "similar biologics" approved in EU fall under the category of erythropoiesis stimulating substances, substances used to stimulate the proliferation and differentiation of granulocytes, follicle stimulating proteins, growth hormones, fast acting insulin and monoclonal antibodies. While the EMA authorizes marketing of "similar biologics", every country in addition retains control over substitution policies, i.e., whether "similar biologics" can be used interchangeably with the reference product. Presently, 24 brands of "similar biologics" have been approved in EU as provided in Table 3 (72). 
JAPAN
In Japan, the Ministry of Health, Labour and Welfare (MHLW) is the regulatory body which is responsible for the evaluation of "similar biologics" in the country. A similar biologic product is designated as a "follow on biological medicinal product" (FOBMP) in Japan(97). It is also termed as "biosimilar product" in several other documents including official documents of the country (98). The Pharmaceuticals and Medicinal Devices Agency (PMDA) of Japan is the regulatory agency that works together with MHLW. The Office of Biologicals of PMDA guides the applicants for "similar biologics" concerning data generation and information submission. The Evaluation and Licensing Division of MHLW through their notification no. 0304007 dated March 04, 2009 issued the guidelines (97) for "similar biologics". The guidelines aim at presenting requirements which are considered for the development of FOBMPs. The guidelines are similar to the EU guidelines and require the applicants to demonstrate that the quality attributes are highly similar to those of the reference biological products. Up to the present time, nine brands of five different kinds of therapeutic-area-specific "similar biologics" have been approved in Japan as per details given in Table 4 (99). 
LATIN AMERICA
All governments are eager to create conditions within their territories to enable the use of "similar biologics" because of increasing financial pressures emanating from the use of reference biologicals. Out of the presently existing 33 sovereign states and 15 dependencies territories, the countries with population of more than 10 million are Brazil, Mexico, Columbia, Argentina, Peru, Venezuela, Chile, Guatemala, Ecuador, Cuba, Bolivia, Haiti and Dominican Republic and their combined population was around 588 million, representing more than 91% of the total Latin American population(100).
Mexico is situated in North America. The Central America houses Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama. The South America comprises Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, French Guinea, Guyana, Paraguay, Peru, Surinam, Uruguay, and Venezuela. The Caribbean countries are another large number of medium and small countries including Cuba, the Dominican Republic, Haiti, Jamaica, Bahamas and Trinidad & Tobago. South America is ethnically and geographically diverse. The first language of most of these countries is Spanish while the Brazilians speak Portuguese. The demographic factors as also the socio-economic conditions are factors distinguishing people from one region to the other. The healthcare business is dominated by the multinational companies from Europe and US. The pharmaceutical sales in Latin American countries was USD 73 billion in 2012, which was around 8% of the global pharmaceutical sales(101). Brazil, Mexico, Argentina and Columbia are the top four economic and pharmaceutical powers in the region.
In this paper, the policies adopted by major Latin American states whose present population was more than 10 million were looked at. The regulations for the approval of "similar biologics" vary considerably among the countries and many
have not yet introduced their guidelines. However most of the counties which have introduced such guidelines have developed theirs mostly taking into consideration the WHO guidelines. Interestingly, in some countries products similar to the reference biological products were already approved without exhaustive clinical testing having been performed. Such steps were taken obviously with a view to make less costly "similar biologics" available to its people by encouraging local manufacture. In Brazil for example where Agência Nacional de Vigilância Sanitária (ANVISA) working under the Ministry of Health of the Brazilian government, is responsible for drug registration and licensing to clients has come out with guidelines on "similar biologics" entitled "Resolução RDC n° 55 de 16 de dezembro de 2010. Dispões sobre o registro de produtos biológicos novos e produtos biológicos e da outras providências" (Resolution no. 55/2010) dated December 16, 2010 elaborating two regulatorypathways (102-103) for "similar biologics". One regulatory pathway is based on a comparative evaluation of the similar biologic with the reference product while the other one is an individual development pathway requiring a reduced dossier where applicants need to generate complete data on quality issues but it does not require these to be comparable. (DOF-19-16-2012) . These decrees are the regulatory instruments related to biotechnological products in Mexico(104). Columbia from its Ministry of Health and Social Protection, known locally as the Ministerio de Salud y Protección Social de Colombia, released its guidelines on "similar biologics" in January 2013. The guidelines are based on generation of information on the 'comparability pathway' matching up the performance with the reference biologic product. The Columbian Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) which is the institute for Drug and Food Surveillance of Columbia, provides the authorization for "similar biologics" for use in the country. On September 18, 2014 the President of Columbia signed a decree defining the ways and the standards that the country would require to register "similar biologics" in Columbia. According to this decree, an "abbreviated route" or "fast track route" for the registration of "similar biologics" will be used utilizing the concept of "comparability" and will ease(105) faster introduction of "similar biologics". In Argentina, the drug registration is authorized by La Administración Nacional de The guidelines for the registration of "similar biologics" were issued by the Venezuelan Instituto Nacional de Higiene Rafael Rangel (INHRR) on 12 th June 2012(110). The guidelines are based on generation of information on "similarity pathway" in terms of quality, safety and efficacy to the reference biopharmaceutical product. Extrapolation for use of indications is not allowed; for this, separate information is to be generated.
The draft guidance for the evaluation of "similar biologics" was published by Chile's El Departamento Agencia Nacional de Medicamentos (ANAMED) in October 2011(111). The country is yet evolving in the setting up of more comprehensive guidelines for the complex "similar biologics". The Ministry of Public Health and Social Assistance of the Government of Guatemala known locally as The Ministerio de Salud Pública y Asistencia Social (MSPAS) had announced its policies for "similar biologics" on 30 th October 2010 through pronouncement of "Technical standard 67-2010" which was later revised(112) on 5 th January 2015. Utilizing these standards the country takes a decision on the use of "similar biologics" in their territory. For Ecuador, the similar biologic guidelines (113) of 2013 take into cognizance the approval procedures. Cuba released (114) its draft guidelines for meeting the requirements for marketing authorization for the approval of non-biological products in October 2010. These guidelines are essentially based on the biosimilar guidelines of WHO (55). Regulations for the faster introduction of "similar biologics" are gradually evolving in several other Latin American countries. A study made some time back on the status of regulations in Latin American countries indicate that many countries have not yet come out with their abbreviated guidelines (115).
The different kinds of "similar biologics" that have been approved in certain Latin American countries are provided as per details given in Table  5 .
AUSTRALIA
The legal framework for approving and regulating medicines in Australia is through their Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) through which the Australian government regulates use of medicine in their country including biologicals. The "similar biologics" are evaluated based on demonstration of comparability in safety, purity and potency with the reference biologics.
The guiding principles are based on applying a risk management approach which is designed to ensure standards of therapeutic goods supplied in Australia to meet the standards of quality, safety and efficacy. The safety assessment is based on scientific and clinical expertise to decision making. The regulation of biosimilar medicines was announced in August 2008 and the guidelines are founded on similar biologic guidelines of the EU. The revised and latest version is Version 2.0 which is effective from 17/12/2015(125). The first similar biologic product approved in Australia was epoetin lamda in January 2010.
Presently, 13 numbers of similar biologic products in18 different brands have been approved in the country as per details given in Table 6 . To treat head and neck cancer; binds to the epidermal growth factor receptor (EGFR) that controls cell division Roche-Rituximab (137) Roche-Herceptin (138) Roche-Avastin (139) To treat anaemia, cancer and chronic kidney failure conditions The Department of Biotechnology up to this period had played a key role in setting standards and in allowing hitherto unapproved recombinant DNA products for experimentation in India under the Environment Protection Act through research mode which enabled this sunrise industry to overcome all the initial teething problems in research and developmental experimentation, which situation was not dealt with by any other Indian law. Thereafter, the "Guidelines on Similar Biologics" were prepared jointly by the Indian Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) for " similar biologic" in 2012 (146) , which was revised and updated in 2016 (147) .India is therefore on a mature footing in dealing with "similar biologics". The Indian industry has gained considerable maturity; there is a pool of trained man-power in place and the statutory authorities have obtained extensive hands-on experience in dealing with modern biological products including "similar biologics".
The different kinds of "similar biologics" that have been approved in India are provided as per details given in Table 7 . Used to replace lost fluid and help restore blood volume in trauma, burns and surgery patients.
To treat advanced squamous cell carcinoma of head and neck. Also used for colorectal cancer treatment
To treat autoimmune diseases To treat autoimmune diseases
Effective for prevention and management of hyperuricemia in patients who are at high risk of developing TLS.
To treat degenerative conditions of the eye SOUTH KOREA The Ministry of Food and Drug Safety (MFDS) of the Government of South Korea through its National Institute of Food and Drug Safety evaluation conducts the scientific evaluation of medicines developed by pharmaceutical companies for use in South Korea. The guidelines on evaluation of biosimilar products were introduced by the country in July 2009; these guidelines were based on the WHO, EU and Japanese guidelines. These guidelines have been revised from time to time incorporating the latest revisions in the notification of 2015(233). The guidelines describe principles of comparability exercise between a reference product and biosimilar product in terms of quality, non-clinical properties and clinical studies. The safety, efficacy and quality of the "similar biologics" are compared with an already marketed reference product. During the developmental stage, the "similar biologics" should be in the same dosage form, posology and root of administration as of the reference product. Other "similar biologics" cannot be used a reference product. The regulatory framework in South Korea is essentially based on a 3-tier system governed firstly by the Pharmaceutical Affairs Act and secondly by notifications of the regulations on review and authorization of biological products and thirdly on the guidelines issued by the country for the evaluation of "similar biologics". Product-based Korean biosimilar guidelines have been published for several products namely erythropoietin, somatropin, granulocyte colony-stimulating factor and monoclonal antibodies (234).
The different kinds of "similar biologics" that have been approved in South Korea are provided as per details given in Table 8 .
CHINA
The Centre for Drug Evaluation at the China Food and Drug Administration issued guidelines on "similar biologics" on 28 th February 2015. According to the Chinese guidelines, a similar biologic product is a "therapeutic biological product" similar to an authorized reference product in terms of quality, safety and efficacy. With reference to clinical studies, the Chinese guidelines suggest that clinical trials for "similar biologics" should start with PK and PD studies based on which clinical efficacy and safety studies should be conducted. The comparability between the similar biologic product and the reference product can be made for quality assessment and non-clinical studies based on clinical PK, PD and PK/PD studies. The Chinese guidelines suggest that the clinical immunogenicity assessment should be based on outcome of non-clinical immunogenicity assessment. When such studies would suggest similarity of the similar biologic product with the reference product then only limited clinical assessment is required. The approval of "similar biologics" has not been assigned to a separate abbreviated approval pathway. The approval pathways are subjected to the same pathways as are applicable to innovative biologics. Further, for the reference product the Chinese authorities require that the product should be approved in China. Reference products approved by foreign regulatory authorities and not approved in China are not acceptable as the reference product. On Interchangeability, no guidelines have yet been elaborated in the Chinese guidelines (242-243). The guidelines do not however specifically incorporate any ICH recommendations in relation to quality, efficacy and safety requirement. Therefore, in essence, though the guidelines are similar to the ones based on WHO and EMA guidelines, in details there are considerable differences. The Chinese guidelines represent a significant progress within the territory for promoting the development of "similar biologics". In the meantime, according to certain reports, a whopping 282 genetically engineered drugs and vaccines have already been approved for commercialization in China of which 21 products are innovative and the rest are copy biologics, according to the data of Southern Medicines Economic Research Institute of the China State Food and Drug Administration as quoted elsewhere(244). All these "similar biologics" are stated to have been approved after Phase III clinical trials.
The first r-DNA product manufactured and marketed in China(245) was recombinant human interferon alpha 1b in 1993 by M/s Shenzhen Kexing Biotech Co. Ltd., Shenzhen. Shenzhen also manufactures erythropoietin and G-CSF(246). Recombinant human interferon alpha 1b is also manufactured by Beijing Tri-Prime Gene Pharmaceutical Co. Ltd. and is marketed as Hapgen injection(247). There are several other full-fledged modern biotech companies in China which include Shenzhen Kangta (248) importing and supplying r-HBV vaccine, Shenyang SanShen manufacturing Interferon, Interleukin 2 and Erythropoietin, Beijing ShuangLu Pharmaceutical Co. Ltd. manufacturing G-CSF, Interleukin 11 and Anhui Anke manufacturing human growth hormone(245).
Hangzhou Jiuyuan Gene Engineering Co. Ltd., Zhejiang is one of the earliest company of China dealing with r-DNA products and it introduced the first biosimilar product in China after Phase III study, the product JILIFENP which is the first rh G-CSF approved in China(249). The company also produces JIJUFEN, which is a recombinant Human Interleukin-11 presented as Injection. Shenzhen Watsin Genetech Ltd., Shenzhen produces recombinant epidermal growth factor and markets the product as GeneTime and GeneSoft (250-251).
In another report on China of 2008 providing information on top 60 Chinese biotech companies, it has been mentioned that majority of the Chinese biotech companies are dedicated to the development and commercialization of follow-on biologics primarily because Chinese investment on R&D is not adequate. Most Chinese biotech firms are small in size (except the China National Biotech Group), most companies do not have adequate fund to take up intensive R&D and to carry out up gradation of facilities to global standards and as a consequence these companies could not obtain western cGMP certification or WHO pre-qualification. Under the present circumstances, outsourcings of technologies are anticipated to be major drivers for the development of China's biotech industry during the next one decade(252).
Presently in China, more than 90% of China's population including the urban employees, urban residents and the rural cooperatives are covered with basic medical insurance. However, as the life expectancy is increasing and as the number of aged population is on the rise and further, as the personal income of a section of population is rising considerably, these conditions would catalyze the expansion of private insurance business for reimbursing the expensive treatment costs of cancer or chronic diseases as these costs are mostly not reimbursed for patients in the existing hospitals (253). Chinese individuals have to meet such costs from out of pocket expenses. These conditions would catalyze the local production of several "similar biologics" in the country.
ASEAN COUNTRIES
The Association of Southeast Asian Nation (ASEAN) represent 10 Member States of ASEAN region comprising Indonesia, Malaysia, Thailand, Philippines, Singapore, Darussalam, Vietnam ,Lao PDR, , Myanmar and Cambodia. The total population in the region during 2012 was estimated(254) at 608.4 million. The ASEAN is committed to creating closer and deeper coordination among the 10 members in economy, society & culture, politics and security through developing single market and production base, raising competitiveness, supporting equitable development and integrating the ASEAN in to the global economy where healthcare improvement of the region is an integral part of the development strategies(255-256).The ASEAN Harmonization Scheme for pharmaceutical harmonization initiative has been taken up to establish cooperation among the ASEAN countries to minimize efforts and to speed their access to new medicines for the people. Efforts initiated in 1992 by creating a Consultative Committee for Standards and Quality and thereafter the Pharmaceutical Product Working Group was established in 1999 where procedures for incorporation of international standards such as ICH and WHO guidelines were incorporated for adoption in the ASEAN Common Technical Dossier (ACTD) for registration of pharmaceuticals for human use (257). However, this document is not meant for use for registration of "similar biologics". Indeed, the ACTD is not yet fully implemented in all ASEAN Member states for biologics and biosimilars (258). Certain countries have however taken steps to register marketing and usage of "similar biologics" in their territory. In Malaysia, for example, the draft guidelines were prepared in March 2008 and were adopted in August 2008(259). Malaysian guidelines have abbreviated pathway in place for registration of "similar biologics". Singapore (260) and Philippines (261) also have their guidelines for "similar biologics". Thailand adopts in-country registration regime for biosimilar products and these registration requirements are aligned with the guidelines of US FDA and European Medical Agency. Thailand has also published specific guidelines for preparing registration application dossier for certain biosimilar products such as erythropoietin, interferon beta, follicle stimulating hormones and monoclonal antibodies. However, incidence of adverse events of pure red cell aplasia in the country has been very high (262) from the use of approved follow-on erythropoietin products indicating therefore that the country has to go a long way in standardization and vigilance procedures. The other ASEAN countries such as Darussalam, Lao PDR, Myanmar and Cambodia are yet to come out with their guidelines for approval of "similar biologics" in their territory. The details of the "similar biologics" approved in ASEAN countries are provided in Table 9 . Data could be obtained for Malaysia and Philippines only.
CIS COUNTRIES
The Commonwealth of Independent States (CIS) is a region which was formed during the breakup of the Soviet Union. Presently, the CIS member countries are Russia, Uzbekistan, Kazakhstan, Belarus, Azerbaijan, Tajikistan, Kyrgyzstan, Moldova and Armenia with a total population of 234.5 million (2015), of which Russia represents around 62.3% followed by Uzbekistan which represents around 13% and Kazakhstan which represents around 7%; the 3 countries together represent about 83% of the CIS countries' population. In terms of per capita GDP, Russia tops the list (US$ 14240 per capita in 2012) followed by Kazakhstan (US$ 11700 per capita in 2012), further followed by Azerbaijan (US$ 7500 per capita in 2012) and Belarus (US$ 6710 per capita in 2012) (271). The market potential of "similar biologics" appears to be more in countries such as Russia, Kazakhstan, Azerbaijan and Belarus. Manufacturers and/or suppliers of "similar biologics" in CIS countries would have to chalk out a slew of initiatives to facilitate faster approval of such products within the territories of each individual country. The pharmaceutical sector in CIS nations is growing at over 10% per year annually in terms of value. However, in these countries most of the expenses on costly medicines are paid individually by patients. Further, most CIS countries do not have the right kinds of infrastructure and expertise to manufacture and test "similar biologics" within their territory. These countries are therefore expected to be dependent upon the availability of such products from cheaper sources without compromising on quality, safety and efficacy. However, even within the existing constraints, several CIS countries have taken steps to introduce "similar biologics" within their territory on a faster mode. The following are the country-wise initiatives taken by the CIS countries in this direction.
RUSSIA
The Russian Federation announced its Federal Law on 12 th April 2010(272) elaborating how biologics including "similar biologics" could be adopted in the country for marketing and use. The law also provided provisions for accelerated marketing approval procedure to biosimilars (273). By October 2015, 14 formulations of G-CSF (filgrastim) were approved for marketing of which 7 were produced locally and another 15 formulations of erythropoietins alpha, beta and theta were also registered in Russia. Of these 15 erythropoietins formulations, 8 were manufactured locally. Neupomax produced by Pharmstandard and Leucostin Neupomax produced by BIOCAD received marketing approval based on limited clinical information. In the country, the state cancer hospitals are able to buy their requirements through electronic auctions. The hospitals submit a bid in common name of the drug and an anonymous contractor can offer the drug quoting lowest price (274). In such a situation of the market condition, introduction of biosimilar product from outside sources seems to be much easier in Russia. Under such policy conditions, local development may get delayed.
OTHER CIS COUNTRIES
There is yet no announced procedure for biosimilar (abbreviated) pathway in place or data/marketing exclusivity for reference biologic products in Uzbekistan, Kazakhstan, Belarus, Azerbaijan, Tajikistan, Kyrgyzstan and Armenia(275) . No information was available on the internet for Moldova. The Republic of Kazakhstan (276) had in the meantime announced its procedures for the marketing approval of "similar biologics" within its territory. Other countries are also poised to develop their guidelines for such products; in the meantime, the existing rules and procedures under the Drugs Act of the CIS countries would be the guiding acts for providing marketing approval of similar biologics within their territories. Without well-laid down procedures however, there would be considerable heterogeneity in the procedures of decision making from one country to the other. In the meantime, these countries would feel the urge for obtaining "similar biologics" by a section of population requiring these medicines to treat several chronic diseases including cancer. Such patients would have to procure these medicines from the local distributors at more expensive prices as there are anticipated to be less marketing competition in these regions.
AFRICAN COUNTRIES INCLUDING SUB-SAHARAN REGION
Africa represents as one of the world's poorest region and therefore a large chunk of diseases are shared by the region. According to the World Health Organization (WHO), the sub-Saharan Africa carries about a quarter of the global dieses burden (277). Presently, national efforts in most African countries to treat childhood diseases by vaccination and communicable anti-microbial diseases by antibiotic and anti-bacterial substances have proven beneficial and such efforts have reduced the mortality to a considerable extent. But yet, the high cost of treatment of life threatening viral diseases (such as HIV, HBV, HCV and others) and chronic health conditions emanating from diabetes, arthritis, cardio-vascular disease conditions and a wide range of cancer requiring long-term treatment by use of biologic drugs which are extremely expensive are putting greater strain on the already resource-poor healthcare system of all African countries. Efforts to make available the cheaper versions of biologic drugs namely the "similar biologics" are therefore a matter of great desire and expectation by the people of the region. The population of Africa region spread in 58 African countries was 1153.3 million as of July 01, 2015, of which population in countries representing individually up to 1% or more, was contributed by 26 nations while larger ones contributing individually to more than 3% of the total were 11; the most populated one was Nigeria, representing nearly 16% of the total African population.
The average annual population growth rate of the entire region was high at 2.68% and in some regions the figures reported were 5.49% at Eritrea and 5.95% in South Sudan (278). Therefore on one hand, while the region is burdened with high population growth rate, poverty enshrouds heavy disease load; on the top of it the induction of In Nigeria, the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) had published the final guidance document for the registration of biosimilar drugs (300) in December 2012. The guidelines are based on the comparability exercise for biosimilar products and are designed to show that the products have highly similar quality attributes when compared to the Reference Biotechnology Product (RBP). RBP is a product used as the comparator for head-to-head comparability studies with a biosimilar product in order to show similarity in terms of quality, safety and efficacy. A bio-therapeutic product that was licensed on the basis of a full registration dossier in Nigeria and / or by a Stringent Regulatory Authority (SRA) can serve as a RBP. Nigeria has defined SRA as the National Drug Regulatory Authorities of countries who are members, observers or associates of the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. A large number of similar biologics have been registered(301) in Nigeria which includes three brands of filgrastim, nine brands of erythropoietin, seventy six brands of insulin including glargine, one brand of streptokinase, one brand of interferon alfa, one brand of luteinizing hormone, one brand of rituximab, two brands of trastuzumab and one brand of ranibizumab. It is however not clear about how many of these biologics are products of original inventors and how many are registered as "similar biologics' or biosimilars. Companies from outside the country have got their biological products registered in Nigeria; the products are being imported and sold in Nigeria as shown in Table11. In other regions of Africa, efforts are being made to catch up and come up with policies for the fast introduction of "similar biologics" in their territories. In the meantime, the load of chronic diseases including cancer continues to rise in this region. At the same time it is to be emphasized that authentic data on the prevalence and mortality due to cancer in the entire African region is particularly sparse. Only a few cancer registries exist in the entire African region and approximately only 8% of the population was covered earlier in such surveys (302) .The published figures are inadequate to accurately assess the population suffering from cancer; it is anticipated that suffers for cancer would be much more. Globally, cancer was identified to be the cause of 15% of all deaths calculated to be about eight million people in 2010, which figure was considered to be greater than the combined deaths caused by HIV, tuberculosis and malaria (303) . There is therefore a great need to pay attention to treating cancer in this region by all countries together and in this context the abundant availability of quality "similar biologics" at affordable costs can play a significant role in human welfare. International bodies like the United Nations (UN), the World Bank (WB) and Multilateral Agencies like the World Health Organization (WHO), Pan American Health Organization (PAHO), The United Nation Children's Fund (UNICEF) and The United Nation Development Programme (UNDP) can be activated jointly by the world community for the global control of chronic diseases especially cancer in poorer African countries by making available effective medicines for treatment. In this context, taking up a project by international bodies to make "similar biologics" available at affordable prices to all poor countries would go a long way in human welfare endeavour.
OTHER COUNTRIES
Presently worldwide there are 197 independent countries of which 193 are the members of the United Nations (304). The population density, disease pattern, per capita GDP, industrialization status, and development of pharmaceutical industries especially the infrastructures for the manufacture of biologicals vary considerably among these countries. In many countries, because of lower population, setting up of facilities for modern biologicals for local consumption is not economically justifiable /feasible. In numerous others, the local capabilities are yet inadequate. There are certain other countries such as Turkey (305) and some others that have made considerable progress in framing their guidelines for the introduction of "similar biologics" in their territories. There are also other countries where guidelines are yet to be formulated (306) . Information from all such regions is not included in this review.
CONCLUDING REMARKS
"Similar biologics" industry is still a nascent one in many countries. The industry is fuelled by expectations of saving/prolonging the lives of patients suffering from certain chronic life-threatening diseases and concomitantly arousing astounding hopes to the society of huge expected savings from their use across the countries. The profitability of "similar biologics" industry is also anticipated to be high. Therefore, the governments, the industry investing in "similar biologics", the payers including the patients are all interested in the development of this industry faster in their territories.
At present, there are globally more than 150 reference biologic products and that about 40 numbers of these have sales of more than USD 1 billion per year. The "similar biologics" are emulating from these reference-biologic products as the "inventor's biologic products" are going offpatent.
If any one or more of the existing or new "similar biologics" companies can capture even 5-10% of the market, these would mean considerable business and profits besides establishment of the image of global presence. This is therefore the right time and a precious opportunity for the entrepreneurs for venturing in to right projects on "similar biologics" in both developing and developed world.
In all countries, the regulations for approval of "similar biologics" are based on proving the comparability of the products to an already approved reference product. The comparability measurements are defined in terms of quality, nonclinical physico-chemical identification of the "similar biologics" as also evaluation of manufacturing processes and finally a clinical evaluation. In all the countries, the abbreviated pathway package requires full quality assessment of the active ingredient by physico-chemical methods using most sophisticated instruments. There is a relaxation however in the generation of data for the finished formulation through comparative clinical studies which situation varies from country to country. All efforts are directed to assess the characteristics of the "similar biologics" with the reference biologics to ensure that the "similar biologics" are as good as the reference biologics.
The liberalization in the extent of data generation for "similar biologics" compared to the corresponding reference biologic drug should not be seen as an issue for conjecturing that "similar biologics" may be inferior to their corresponding reference biologic drug counterpart. All "similar biologics" are required to be physico-chemically, biologically and immunologically similar to the reference products at the time of marketing authorization and approval. The relaxation in the generation of extensive clinical data through comparative clinical studies is on the assumption that extensive data had already been generated earlier for the reference biologics and that exhaustive duplication would lead to increase in costs of development, which can be avoided. This would also ease faster introduction of "similar biologics" to serve the patients.
Even though the evaluation criteria for the approval of "similar biologics" are based on proving the comparability of the products to an already approved reference product, regulators of several developed countries presently believe that data generation and documentation are not exhaustively standardized and therefore data generated in one country cannot always be accepted in another country. As a result, manufacturers are required to generate some part of comparability information once again when they wish to register their "similar biologics" in such newer regions.
Every "similar biologic" product is also named by the manufacturer by an international nonproprietary name (INN) on the label besides its brand name. Even though "similar biologic" products are approved by the regulators only after being convinced that these are comparable physico-chemically, biologically and immunologically to the reference product and that these are as safe and as efficacious as the reference biologic, several countries strongly feel that for post-market surveillance for pharmacovigilance purposes each "similar biologic" should be distinctly identifiable even from their INN. In other words, the INN for "similar biologics" needs modification. Scientifically, while every new pharmaceutical formulation introduced in to the market requires pharmacovigilance in order to ensure long-term safety, addressing the problem for "similar biologics" through INN modification does not seem to be the most desirable way firstly because alteration of INN distorts an established scientific understanding and secondly because this process may foster an impression that "similar biologics" may be an inferior product. The very purpose of introducing simplified procedures for fast introduction of "similar biologics" at more affordable prices to serve the ailing patients gets diluted. The surmountable efforts of entrepreneurs to develop more competitive "similar biologic" technologies all over the world also gets a jolt.
One alternative way to identify is to prefix or suffix a code for each new-entrant "similar biologics" on the brand name instead on the INN; for companies introducing "similar biologics" only in INN , the prefix or suffix be added on the INN for them.
The "inventor's biologic products" have contributed significantly during the last three decades in treating chronic diseases including cancer. "Similar biologics" are subsets of inventor's biologics. It is anticipated therefore that introduction of "similar biologics" of quality proven to be comparable to the "inventor's biologics" and available at cheaper prices would enable more usage of such products for treating more patients and the situation shall contribute considerably more to human welfare at more affordable costs.
Although "similar biologics" are essentially very similar to the inventor's biologics, the technologies for their manufacture are not simple. The business is highly science and technology based. High technical skill, strong discipline and maintenance of uniform conditions throughout the processing cycles are the cornerstones for success in order to minimize batch to batch variations in the product qualities. Countries developing "similar biologics" industries get technologically elevated in multiple facets.
At the present moment, all countries throughout the world do not have a uniform policy standard for approval process for "similar biologics". While the developed countries are making fast progress, the space for the highly populated developing countries entering in to this business is to first feed its own country and then to venture to enter in to the regions of developed country markets, where feasible. It is anticipated that baring a few, most developing countries would find it difficult to get their "similar biologics" registered in developed country markets for the time being; the developing countries would have to gather more experience, especially in technological aspects. Sadly, in several developing countries, the existing infrastructure is inadequate for the establishment of "similar biologics" industries.
For becoming a prominent player in "similar biologics" from the developing countries all round development and up gradation is required. In this context while the local regulatory authorities need to be upgraded with matching infrastructure, concomitantly institutional skill development as well as the R&D infrastructure of the country in modern biology need to be upgraded. Medical infrastructure should be strong. Efficient bio-based industries should be in place. In addition, every opportunity should exist for collaborations with technologically rich countries and companies. These are some of the important factors on which developing countries can ponder to establish their "similar biologics" industry in their territories on a strong footing. 
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